Identification of imaging biomarkers for the assessment of tumour response to different treatments in a preclinical glioma model

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 42, Issue 7, 2015, Pages 1093-1105

  Lo Dico, A ^a   Martelli, C ^a   Valtorta, S ^b,c   Raccagni, I ^c,d   Diceglie, C ^a   Belloli, S ^b,c   Gianelli, U ^a,e   Vaira, V ^e,f   Politi, L S ^c   Bosari, S ^a,e   Lucignani, G ^a,g,h   Moresco, R M ^c,d   Ottobrini, L ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b CNR   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

^e MAGGIORE HOSPITAL   (Italy)

^f Istituto Nazionale di Genetica Molecolare   (Italy)

^g UNIVERSITY OF MILAN   (Italy)

^h SAN PAOLO HOSPITAL   (Italy)

Author keywords

Biomarker; CAIX; HIF 1alpha; Optical imaging; Temozolomide

Indexed keywords

ANTINEOPLASTIC AGENT; CARBONATE DEHYDRATASE; DACARBAZINE; HIF1A PROTEIN, HUMAN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PHOTOPROTEIN; TEMOZOLOMIDE; TUMOR MARKER;

ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; DRUG SCREENING; FEMALE; FLUORESCENCE IMAGING; GENETICS; GLIOMA; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CARBONIC ANHYDRASES; CELL LINE, TUMOR; DACARBAZINE; DRUG EVALUATION, PRECLINICAL; FEMALE; GLIOMA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LUMINESCENT PROTEINS; MICE; MICE, NUDE; OPTICAL IMAGING;

EID: 84939934765     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-015-3040-7     Document Type: Article

References (54)

1. Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurg Focus 2006;20(4):E24.
2. Rankin EB, Rha J, Unger TL, Wu CH, Shutt HP, Johnson RS, et al. Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice. Oncogene 2008;27(40):5354–8.
3. Rapisarda A, Zalek J, Hollingshead M, Braunschweig T, Uranchimeg B, Bonomi CA, et al. Schedule-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts. Cancer Res 2004;64(19):6845–8.
4. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, et al. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 2000;60(6):1541–5.
5. Chen Z, Htay A, Dos Santos W, Gillies GT, Fillmore HL, Sholley MM, et al. In vitro angiogenesis by human umbilical vein endothelial cells (HUVEC) induced by three-dimensional co-culture with glioblastoma cells. J Neurooncol 2009;92(2):121–8.
6. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, et al. Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol 2007;72(1):162–72.
7. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W, et al. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 2006;12(15):4523–32.
8. Ma J, Murphy M, O’Dwyer PJ, Berman E, Reed K, Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 2002;63(7):1219–28.
9. Hegi ME, Diserens A-C, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003.
10. Kanzawa T, Germano IM, Komata T, Ito H, Kondo Y, Kondo S. Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells. Cell Death Differ 2004;11(4):448–57.
11. Natsumeda M, Aoki H, Miyahara H, Yajima N, Uzuka T, Toyoshima Y, et al. Induction of autophagy in temozolomide treated malignant gliomas. Neuropathology 2011;31(5):486–93.
12. Shen W, Hu JA, Zheng JS. Mechanism of temozolomide-induced antitumour effects on glioma cells. J Int Med Res 2014;42(1):164–72.
13. Lewis JS, Achilefu S, Garbow JR, Laforest R, Welch MJ. Small animal imaging. Current technology and perspectives for oncological imaging. Eur J Cancer 2002;38(16):2173–88.
14. Massoud TF, Gambhir SS. Integrating noninvasive molecular imaging into molecular medicine: an evolving paradigm. Trends Mol Med 2007;13(5):183–91.
15. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, et al. Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 2009;8(7):1867–77.
16. Lohar MV, Mundada R, Bhonde M, Padgaonkar A, Deore V, Yewalkar N, et al. Design and synthesis of novel fluoroquinolone based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway. Bioorg Med Chem Lett 2008;18(12):3603–6.
17. Creighton-Gutteridge M, Cardellina 2nd JH, Stephen AG, Rapisarda A, Uranchimeg B, Hite K, et al. Cell type-specific, topoisomerase II-dependent inhibition of hypoxia-inducible factor-1alpha protein accumulation by NSC 644221. Clin Cancer Res 2007;13(3):1010–8.
18. Persano L, Pistollato F, Rampazzo E, Della Puppa A, Abbadi S, Frasson C, et al. BMP2 sensitizes glioblastoma stem-like cells to temozolomide by affecting HIF-1α stability and MGMT expression. Cell Death Dis 2012;3:e412.
19. Lo Dico A, Valtorta S, Martelli C, Belloli S, Gianelli U, Tosi D, et al. Validation of an engineered cell model for in vitro and in vivo HIF-1α evaluation by different imaging modalities. Mol Imaging Biol 2014;16(2):210–23.
20. Kapoor GS, O’Rourke DM. Receptor tyrosine kinase signaling in gliomagenesis: pathobiology and therapeutic approaches. Cancer Biol Ther 2003;2(4):330–42.
21. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7(7):1851–63.
22. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, et al. Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging 2011;3(3):192–222.
23. See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res 2012;72(13):3350–9.
24. Glassmann A, Reichmann K, Scheffler B, Glas M, Veit N, Probstmeier R. Pharmacological targeting of the constitutively activated MEK/MAPK-dependent signaling pathway in glioma cells inhibits cell proliferation and migration. Int J Oncol 2011;39(6):1567–75.
25. A phase I/II study of BEZ235 in patients with advanced solid malignancies enriched by patients with advanced breast cancer. ClinicalTrial.gov Identifier number: NCT00620594.
26. Efficacy and safety of the combination therapy of dabrafenib and trametinib in subjects with BRAF V600E- mutated rare cancers. ClinicalTrial.gov Identifier number: NCT02034110.
27. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352(10):987–96.
28. Maes W, Deroose C, Reumers V, Krylyshkina O, Gijsbers R, Baekelandt V, et al. In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma. J Neurooncol 2009;91:127–39.
29. Galldiks N, Kracht LW, Burghaus L, Ullrich RT, Backes H, Brunn A, et al. Patient-tailored, imaging-guided, long-term temozolomide chemotherapy in patients with glioblastoma. Mol Imaging 2010;9(1):40–6.
30. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci U S A 2009;106:22299–304.
31. Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A, et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010;70(20):8097–107.
32. Liu TJ, Koul D, LaFortune T, Tiao N, Shen RJ, Maira SM, et al. NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther 2009;8:2204–10.
33. Gilmartin AG, Bleam MR, Groy A, Moss KG, Minthorn EA, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011;17:989–1000.
34. Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E, et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 2012;11(3):720–9.
35. Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Pathway inhibition: emerging molecular targets for treating glioblastoma. Neuro Oncol 2011;13(6):566–79.
36. Semenza GL, Nejfelt MK, Chi SM, Antonarakis SE. Hypoxia-inducible nuclear factors bind to an enhancer element located 3′ to the human erythropoietin gene. Proc Natl Acad Sci U S A 1991;88(13):5680–4.
37. Ke Q, Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol Pharmacol 2006;70(5):1469–80.
38. Welsh SJ, Koh MY, Powis G. The hypoxic inducible stress response as a target for cancer drug discovery. Semin Oncol 2006;33(4):486–97.
39. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008;8(12):967–75.
40. Munoz JL, Rodriguez-Cruz V, Greco SJ, Ramkissoon SH, Ligon KL, Rameshwar P. Temozolomide resistance in glioblastoma cells occurs partly through epidermal growth factor receptor-mediated induction of connexin 43. Cell Death Dis 2014;5:e1145.
41. Mathieu V, De Nève N, Le Mercier M, Dewelle J, Gaussin JF, Dehoux M, et al. Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia 2008;10(12):1383–92.
42. Vlachostergios PJ, Hatzidaki E, Befani CD, Liakos P, Papandreou CN. Bortezomib overcomes MGMT-related resistance of glioblastoma cell lines to temozolomide in a schedule-dependent manner. Invest New Drugs 2013;31(5):1169–81.
43. Salskov A, Tammisetti VS, Grierson J, Vesselle H. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[18F]fluorothymidine. Semin Nucl Med 2007;37(6):429–39.
44. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, et al. Kinetics of 3′-deoxy-3′-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med 2010;51(5):720–7.
45. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677–84.
46. Kaluz S, Kaluzová M, Liao SY, Lerman M, Stanbridge EJ. Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 2009;1795(2):162–72.
47. Hoeben BA, Kaanders JH, Franssen GM, Troost EG, Rijken PF, Oosterwijk E, et al. PET of hypoxia with 89Zr-labeled cG250-F(ab′)2 in head and neck tumors. J Nucl Med 2010;51(7):1076–83.
48. Lau J, Zhang Z, Hundal-Jabal N, Liu Z, Benard F, Lin KS. Synthesis and evaluation of monomeric, dimeric and trimeric benzenesulfonamide derivatives for imaging carbonic anhydrase IX with PET. J Nucl Med 2014;55(Suppl 1):444.
49. Surfus JE, Hank JA, Oosterwijk E, Welt S, Lindstrom MJ, Albertini MR, et al. Anti-renal-cell carcinoma chimeric antibody G250 facilitates antibody-dependent cellular cytotoxicity with in vitro and in vivo interleukin-2-activated effectors. J Immunother Emphasis Tumor Immunol 1996;19(3):184–91.
50. Bleumer I, Knuth A, Oosterwijk E, Hofmann R, Varga Z, Lamers C, et al. A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients. Br J Cancer 2004;90(5):985–90.
51. Hubbi ME, Hu H, Kshitiz, Ahmed I, Levchenko A, Semenza GL. Chaperone-mediated autophagy targets hypoxia-inducible factor-1α (HIF-1α) for lysosomal degradation. J Biol Chem 2013;288(15):10703–14.
52. Ferreira JV, Fôfo H, Bejarano E, Bento CF, Ramalho JS, Girão H, et al. STUB1/CHIP is required for HIF1A degradation by chaperone-mediated autophagy. Autophagy 2013;9(9):1349–66.
53. Finn PF, Mesires NT, Vine M, Dice JF. Effects of small molecules on chaperone-mediated autophagy. Autophagy 2005;1(3):141–5.
54. Yamaki H, Nakajima M, Seimiya H, Saya H, Sugita M, Tsuruo TJ. Inhibition of the association with nuclear matrix of pRB, p70 and p40 proteins along with the specific suppression of c-MYC expression by geldanamycin, an inhibitor of Src tyrosine kinase. J Antibiot 1995;48(9):1021–6.